J P M O R G A N Global FX Strategy 06 June 2025 Key Currency Views All beautiful things must come to an end Figure 1: Growth is projected to decline in the US and several countries in 2025, but there are several winners as well: Antipodeans, NOK, EUR and JPY in DM and EMEA in EM J.P. Morgan economists' growth forecasts for 2025 vs. actual in 2024 See page 48 for analyst certification and important disclosures. J.P. Morgan does and seeks to do business with companies covered in its research reports. As a res ...

Core Viewpoint - Goliath Resources Limited has amended the exercise price of common share purchase warrants related to its recent private placements, which include a "bought deal" offering and a concurrent offering, with the new exercise price set at C$2.12 per share [4]. Group 1: Offerings and Financial Details - The Company is conducting a "bought deal" private placement of 6,310,000 common shares at a price of C$3.17 per share, aiming for gross proceeds of C$20,002,700 [1]. - A concurrent offering of up to 1,281,545 Charity Flow-Through Shares is also being conducted at the same price of C$3.17 per share, targeting gross proceeds of up to C$4,062,500 [1]. - The Underwriters will receive a cash commission of 6.0% of the gross proceeds from the Bought Deal Offering and warrants equal to 6.0% of the shares sold [2]. - Finders involved in the Concurrent Offering will receive a similar compensation structure, including a cash fee of 6.0% and warrants [3]. Group 2: Amendments and Regulatory Approvals - The exercise price for both the Broker Warrants and Finder's Warrants has been amended from C$1.95 to C$2.12 per common share, while other terms remain unchanged [4]. - The closing of both the Bought Deal Offering and the Concurrent Offering is subject to regulatory approvals, including that of the TSX Venture Exchange [5]. Group 3: Company Background - Goliath Resources Limited is focused on exploring precious metals projects in the Golden Triangle of northwestern British Columbia, with all projects located in favorable geological and geopolitical settings [7]. - The Company has strategic cornerstone shareholders, including Crescat Capital and McEwen Mining Inc., indicating strong backing in the industry [7].

Hong Kong, China, June 09, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3e Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, today announced the pricing of up to $7.4 million aggregate principal amount of senior convertible secured notes (the “Notes”) to be issued in three tranches, and accompanying warrants (the “Warrants”), in a private placement (the “Offering”) to an institutional investor (the “Investo ...

US trade officials meeting their Chinese counterparts in London to continue trade talks. The trade policy uncertainty just one of the many layers of worries hanging overhead for the US economy. For more, we bring in Princeton University professor Alan Blinder, former Fed vice chair.He also served as a member of President Clinton's Council of Economic Advisors. Alan, it's always great to get your perspective. I know you also recently wrote about uh more broadly some of the policies of the Trump administratio ...

2025 年 6 月 5 日，加州大学欧文分校的研究人员在 Cell 子刊 Cell Stem Cell 上发表了题为： Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins 的研究论文。 该研究利用 CRISPR 基因编辑修饰的 人类诱导多能干细胞来源的小胶质细胞 （iMG） ，实现了 中枢神经系统 （SNS） 范围内的疾病修正蛋白递送，并验证了 撰文丨王聪 编辑丨王多鱼 排版丨水成文 血脑屏障 （Blood-Brain Barrier，BBB）， 是指脑毛细血管壁与神经胶质细胞形成的血浆与脑细胞之间的屏障，和由脉络丛形成的血浆和脑脊液之间的屏障，仅 允许特定类型的分子从血流进入大脑神经元和其他周围细胞。 血脑屏障的存在，对于阻止有害物质由血液进入大脑具有重要意义，但这也同时阻止了绝大部分小分子和大分子药物 （例如多肽，蛋白质和核酸） 的转移，严重 限制了中枢神经系统疾病 （例如神经退行性疾病、脑肿瘤，脑部感染和中风等） 的治疗。 尽管该领域近年来取得了一些进展，但我们仍然迫切需要能够跨越血脑屏 ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha 4 June 2025 | 6:00PM HKT Hong Kong: Decoding the recent moves in HKD FX/Rates market Bottom line: USD/HKD spot hit the lower bound (strong side) of the band (7.75) in early May amid broad USD weakening (and the very sharp appreciation of the Taiwan Dollar specifically). This prompted Hong Kong Monetary Authority (HKMA) intervention to sell HKD and buy USD, more than tripling interbank liquidity in Hong Kong. The surge in interbank liquidity led to a sharp drop in front-end HK ...

证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-06-06 [Table_Tag] 宏观策略 [Table_MacroStrategy] 宏观深度报告 20250603：复盘 200 年，贸易战何去何从？ 通过复盘自 1800 年至今 200 余年的全球贸易历史，以及结合近期东部沿 海省份"造船厂-船东-船公司-货代及外贸公司-实体制造业"外贸产业链 调研反馈，我们的研究表明： 首先，复盘全球贸易历史看，汇率、非关 税壁垒可能取代关税成为更加关键的"贸易交锋"工具。 其次，国内多 数外贸企业认为由于在根本矛盾上的冲突，中美贸易谈判过程未来或将 "一波三折"，企业可能需要持续控制对美出口风险敞口。 再次，如果加 征关税无法实现美方贸易竞争的主要目的，那么参考过去 200 年全球贸 易历史特别是 1970s-1990s 美日德贸易竞争阶段的美方举措，未来美国政 府可能在非关税壁垒、汇率等方面发起更多挑战。 最后，在控制对美出 口风险敞口的过程中，拓展非美出口、"出口转内销"、"出海"等关键手 段仍待企业端摸索落地方式，年内外贸前景仍面临高度不确定性。 宏观深度报告 20250602：人民币汇率：会否升 ...

Key Takeaways Palo Alto Networks' NGS ARR hit $5.09B in Q3 of fiscal 2025, growing 34% year over year. XSIAM bookings neared $1B as ARR from the AI platform soared more than 200% year over year. PANW now has 130 customers with $5M in NGS ARR, and 44 customers surpassing $10M .Palo Alto Networks (PANW) surpassed a key milestone during the third quarter of fiscal 2025, wherein the annual recurring revenues (ARR) for its next-generation security (NGS) solutions hit the $5 billion mark. In the third quarter, ...

Vaxcyte (PCVX) 2025 Conference June 05, 2025 09:55 AM ET Speaker0 Alright. Welcome, everyone, to twenty twenty five Jefferies Global Healthcare Conference. My name is Roger Song, one of the senior analysts covering mid cap biotech in The US. It's my pleasure to introduce next presenting company, Backside. So we have a whole crew here. We're gonna have a fireside chat with the CEO, Grant, president and CFO, Andrew, and then COO, Jim. Good morning, gentlemen. Speaker1 Good morning, Roger. Good morning. Speake ...

Financial Data and Key Metrics Changes - The company reported a strong first quarter with an ARR growth of 6% year over year, exceeding guidance for revenue and diluted EPS [6][13] - Revenue for Q1 was $208 million, with non-GAAP diluted EPS at $0.29, driven by the timing of two large unbundled SaaS deals [13][18] - The company expects to exit the year with approximately $768 million in ARR, reflecting an 8% year-over-year growth [15][18] Business Line Data and Key Metrics Changes - AI ARR increased by 24% year over year, reaching $354 million, now representing close to 50% of subscription ARR [17][18] - The company won significant deals, including a $13 million TCV order from an insurance company and a $14 million TCV order from a healthcare company, showcasing strong demand for AI solutions [8][9] Market Data and Key Metrics Changes - The rolling four-quarter SaaS pipeline has increased by more than 30% year over year, indicating strong demand for AI [15][19] - The company maintains a total of 4 million seats under management, with some customers reducing agent numbers due to AI adoption while others expand [36][38] Company Strategy and Development Direction - The company focuses on transforming AI technology into tangible business outcomes, emphasizing a hybrid cloud model that allows customers to layer AI on existing infrastructures [7][10] - The strategy includes starting small with AI deployments, allowing customers to scale once they prove value [27][30] - The company aims to maintain its differentiation through strong customer relationships, a platformatic view of AI integration, and an open AI model that incorporates various AI technologies [75][78] Management's Comments on Operating Environment and Future Outlook - Management noted a shift in customer focus towards value and ROI, with less interest in long-term projects and more emphasis on immediate results [64][66] - The company expects continued momentum in AI adoption, with a target of double-digit free cash flow growth alongside 8% ARR growth [12][21] Other Important Information - The company has increased its revolver to $500 million and extended the term to 2030, which can be used to pay down existing convertible notes [20] - The management highlighted the importance of customer success stories in driving AI adoption and plans to showcase these at an upcoming customer conference [47][48] Q&A Session Summary Question: How does Verint differentiate itself in the AI space? - Management emphasized proven AI outcomes and the ability to layer AI on existing infrastructure as key differentiators [25][26] Question: Can you provide examples of successful smaller deals leading to larger contracts? - Management shared examples of customers increasing their AI consumption significantly after initial small deployments, leading to larger ARR contributions [29][30] Question: What is the current state of AI voice chatbot adoption? - Management noted that while some customers are reducing agent numbers, the overall number of agents remains stable, with AI driving significant growth in ARR [36][38] Question: What is the outlook for the second half of the year regarding ARR? - Management expressed confidence in achieving the 8% ARR growth target, supported by a strong pipeline and seasonal trends [54][56] Question: How is the company addressing customer concerns about AI adoption? - Management highlighted the importance of demonstrating value quickly and encouraging customers to move to production rather than remaining in lab experiments [66][90]